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relationto tha underlyingpathologicsubstrata.Since 1979, clinical histoty
and autopsy findings have been prospectively analysed in 218 young SCD
victims (155 frIdeS, 63 femaleS, aged 1 to 35 yeara, mean 24.2). One hun-
dred and five (48%) patients (pfs) experienced prodromal symptoms within
2 yeara preceding SCD: In the other 113 pts SCD was the first manifestation
of disease. Ninety-five (44Yo) pfe had minor symptoms such as palpitations
in 52, dizziness in 24, weakness in 20, efforl dyspnea in 18, and non specific
chest pain in 10. Major, warning prodroma occurred in 53 (24%) pts and
consisted of syncope in 47 (exercise-related in 29 and reeurrent in 12), and
transient cardiac arrest In 6. At autopsy, SCD was ascribed to cardiomyopa-’
thy in 55 pta, atherosclerotic corona~ artery disease in 44, valve disease
in 28, non-athemsclpmtlc comna~ artery disease in 26, conduction system
pathology in22, myocatdltis in 22, aortlc rupture in 12, postoperative congen-
ital hearfdlsease In 5, and pulmonary thromboembdlsm in 4. Although minor
symptoms were unrelated to the underfylng cardiac disease, syncope and
cardiac arrest were significantly (p < 0.01) asswiated with cardiomyopathies
(“right ventricular” and “hypertrophic”) as well as conduction system abnor-
malities (acaeseoty pathways and sclerotic lesions). In conclusion, 48% of
young SCD victims hart experienced pmdromal symptoms before the fa-
tal evant, Syncopal epfsodes and transient cardiac arrest preceded 24%
of SCDS and were significantly related to cardiomyopathy and conduction
system pathology.
D96763 Forced Expiatory Volume In 1 Sacond iss Strong
snd Independent Predictor of Cardiovascular
Death. Reeults Froms 22-Year Follow-up Suwey
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Nor onlyconventional risk factors, but also reduced organ function may be
used to predict rfskof cardlovaacular death (CVD). Forced exploratoryvolume
In one second (FEVI) was measured in 2014 apperantly healthy men aged
40-59 years during an extensive cardiovascular soreening survey in 1972-
74 including spimgrafictests, bloodtests, resting ECG and a symptom limited
bicycle exercise test. Twenty-two years mortality data (ICD 9 classification)
revealed total mortality of 23.8% with cardiovascular death accounting for
53.8%. FEV1 was ranged between 0.S-6.05 Litera (L).
FEV1 CVmortaliry Non-CVmortality
s 2.95 L (n= 501) 17.3”A 17.2%
2.96-3.45L (n = 501) 12.9”A 10,2%
3.4S-3.S0 L (n = 512) 11.1% 9.2%
>3.90 L (n = 477) 7.9”A 7.4%
The table demonatratea that reduced lung function ia related to risk of CV-
and non-OV mortality. Similar mortality gradients were seen in amokers and
non-amokere, but most pronounced in the latter.
In conclusion, aowrding to Cox regression analyais, accounting for age
and amoking habits, FEVI is a strong and independent predicforfor all cause
nwtality. FEV1 <2.95 L increases mortality risk significantly, RR= 2.0 (95Y0
Cl: 1.4-2.9; p < 0.001).
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We conducted this study to assess the impact of home intravenous in-
otmpic therapy (HIT) on cost and clinical outcomes (hospital admissions,
total length of hospital stay, NYHA class, mortality) in advanced heart failure
(HF). Twenty-four patients (61 + 12 years; 13 males) with cardiomyopathy
(ejection fraction 0.17 +0.06; 14ischemic) and NYHAClaas IV HF refracto~
to oral medications received HIT for at least 1 month between May 1994 and
April 1996. Inotropic agents used were dobutamine (5.0 + 2.2 @kg/rein; n
= 17), milrinone (0.53 + 0.05 wg/k@min; n =4) or a combination of both (n
=3) administered aa continuous (24 hr.s/day;n = 17) or intermittent infusion
fora mean duration of 3.9 + 2.7 months. Duration of HIT was the designated
study period. The immediate preceding period (of equal duration) in each
patient was designated as the control period. Costa were calculated from
total charges and cost charge ratios and adjustad to 1996 US dollars (USD).
Total cost was defined as the sum of hospital, outpatient, and home health
costs. f?esu/ts:Compared to the control period, the study period showed a
decrease in hospital admissions (2.7+ 2.6 vs 1.3 + 1.3; p = 0.04), Iangth of
stay (20.9 + 12.7 vs 5.5 + 5.4 days; p < 0.0001) and improvement in NYHA
class (4.0 + O.OVS2.7 + 0.9: p < 0.0001). Additionally, a 16% reduetion
in cost was seen in the atudy period (31.0 + 26.0 vs 36.7 + 20.9 thousand
USD), amounting to a savings of USD 5,715/patient or 1,465/patient/month.
Eight patients died from progressive HF (n = 7) or sudden cardiac death (n=
1) after 2.8 + 1.7 months of HIT. Corrc/usiorr;In addition to improving func-
tional class and need for hospitalizations, HIT reduces total cost in selected
patients with advanced HF.
n96852 Onca Dsily Medications Improve Quality of Life in
Stable Angina: 6 Month Follow-Up
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Puget Sound VAMedical Center, Seaffle, WA, USA
The Qualify of Life and Angina Resaarch Trial (QUART) is a randomized,
single-blind trial comparing once daily medioationa (QD) with multi-dosing
(MD) regimens for the treatment of stable angina. Methods: 107 men were
randomly allocated to either their current anti-anginal regimen (MD) or to a
once daily regimen (QD). Angina treatment was optimized for both groups
using a standardized protocol and patients were followed for 6 months. The
primary outwmes were quality of life (QOL) scores as measured by the
Saeffle Angina Questionnaire (SAQ) and Short Form Health Survey (SF-36).
Both SAQ and SF-36 scoree range from Oto 100, higher scores raflacfing
better function. Results: Sixty-eight % had prior Ml, hypertension (75%), de-
pression (37%), arthritis (61%), and diabetes (39%). No difference were
found between baseline demographic, medication, or QOL scores in the 54
(MD) and the 53 (QD) patients. At 3 months, the QD group demonstrated
highly significant improvements In angina frequency, angina stability, treat-
ment satisfaction, social functioning and mental health scores over the MD
group. At 6 months, these treatment effects were sustained atthesame level,
with no further improvements noted in either group. Both groups experienced
significant improvements in overall quality of life and neither group experi-
enced improvements in physical limitations. Conclusion: In stable angina,
once daily medications are more efficacious in improving quality of life than
multi-doaing medication regimens. This is sustained over 6 months.
Saaelineto 3 MonthsMean Change Scores
MD Group QD Group P
AnginaFrequsncy 4.4 19,1 0.002
AnginaStability 4.s 20.2 0.01
Treatment Satisfaction 3.1 5.9 0.04
Social Functioning –0.53 10.1 0.05
Mental Health –0.93 7.1 0.01
-[ whYareHea~~ai,ur.~atientswi~h~efiVentri.ular
Dysfunction not Receiving Angiotensin-Converting
Enzyme Inhibitors?
B.A. Bart, S.J. Diem, C.M, O’Connor. Duke University Medics/ Cente~
Durham, NC, USA
The banefifa of angiotensin-wnverting enzyme (ACE) inhibition in patients
with left ventricular dyafuncfion are established; however, 20% to 50% of
such patients with cortgeative heart failure do not receive ACE inhibitors.
To summarize the use of and reasons for nonuse of these drugs in such
a population, we reviewed the medical rewrds of 242 patients admitted to
Duke from 7/1/92 to6/30/93 with a principal diagnosis of CHFand an ejehion
fraction S 45%.
Twenty-four percent of these patients did not receive ACE inhibitora,
bacauae of contraindications (10%), drug intolerance (5%), or unknown rea-
sons (8%). Creatinine and syatolic blood pressure in the unknown group were
normal (median values 1.3 mg/dL and 139 mm Hg, respectively). Patients
treated with ACE inhibitors had lower ejection fractions (median 20% versus
30%, P = 0.0048) and lower comorbidity scores (median 3 versus 4, P =
0.0004) than patients not so traated. There were no significant differences
in NYHA classification, sex, race, age, or etiology of CHF between patienta
receiving ACE inhibitora and thoae not so treated.
Conclusion: A large proportion of patients not receiving ACE inhibitor
therapy (35%) have no apparent reason for the lack of such treatment.
Strategies to increase the uae of these agents should be explored and
encouraged.
